← Latest papers
📄 cell biology

Fatty acid synthase coordinates mTOR signaling and histone crotonylation during cardiomyocyte hypertrophy

This study identifies fatty acid synthase (FASN) as a critical regulator that drives cardiomyocyte hypertrophy by activating mTOR signaling and enhancing histone crotonylation, thereby linking altered lipid metabolism to epigenetic dysregulation in pathological cardiac remodeling.

Original authors: Ntorla, A., Coleman, P., Xia, Y., Warren, H. R., Burgoyne, J. R.

Published 2026-10-30
📖 5 min read🧠 Deep dive

Original authors: Ntorla, A., Coleman, P., Xia, Y., Warren, H. R., Burgoyne, J. R.

Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). ⚕️ This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer

The human heart is a tireless engine, but when it faces constant stress, it does something unexpected: it tries to grow stronger by getting bigger. This process, known as hypertrophy, is the heart's way of coping with high blood pressure or other strains. However, this growth often goes wrong. Instead of becoming a more efficient pump, the heart muscle thickens in a disorganized way, eventually leading to heart failure. For decades, scientists have looked at the heart's genetic code and the physical forces acting on it to understand why this happens. But a newer, quieter layer of control has emerged as a critical player: the way the heart's DNA is packaged and read. Inside every cell, DNA is wrapped around spool-like proteins called histones. Chemical tags can be added to these spools, acting like volume knobs that turn genes up or down without changing the underlying code. One such tag, called crotonylation, has recently been identified as a powerful switch that can crank up the volume on genes involved in heart growth. The question researchers now face is simple yet profound: what triggers this switch to turn on in a failing heart?

A team of scientists at King's College London has traced the origin of this switch to a surprising source: the heart's own fat-making machinery. In a study published in a preprint, the researchers discovered that a specific enzyme, which normally helps cells build fatty acids, acts as a master coordinator during heart stress. This enzyme, known as fatty acid synthase, or FASN, does not just manage fat; it also signals the heart's growth machinery to activate a specific chemical tag on the DNA spools. This tag, histone crotonylation, effectively unlocks the genes that drive the heart to enlarge. The team found that when the heart is stressed, FASN levels rise, which in turn boosts a signaling pathway that tells the DNA packaging to add more of these crotonylation tags. This chain of events leads directly to the expression of genes that cause the heart muscle cells to grow larger.

The researchers did not just observe this connection; they tested it by breaking the chain at different points. When they used genetic tools or drugs to stop FASN from working in heart cells, the surge in crotonylation tags disappeared. More importantly, the heart cells stopped growing larger in response to stress. This suggests that FASN is not merely a bystander but a necessary driver of this specific type of heart growth. The team also looked at what happens in the heart's signaling network. They found that FASN works closely with another well-known growth regulator, a protein called mTOR. When FASN is active, it helps turn on mTOR, which then activates a protein called p300. This p300 protein is the actual worker that adds the crotonylation tags to the DNA. In a stressed heart, the researchers noticed a shift in how p300 behaves: it stops adding a different chemical tag called acetylation and starts adding crotonylation instead. This switch in activity appears to be the key mechanism that turns on the genes responsible for the heart's pathological enlargement.

To ensure these findings were not just a laboratory artifact, the team looked at real human data. They analyzed genetic information from patients with a condition called hypertrophic cardiomyopathy, a disease where the heart muscle becomes abnormally thick. In these patients, the levels of FASN in the heart tissue were strongly linked to the levels of genes known to drive heart growth. Furthermore, the researchers examined the human genome and found a specific genetic variation near the FASN gene. People who carry this variation are more likely to have higher levels of FASN in their heart cells and are also more likely to have heart failure listed as the underlying cause of death. This genetic link suggests that the relationship between fat-making enzymes and heart growth is not just a temporary reaction to stress but may be hardwired into our biology for some people.

The study also clarified what is not causing this problem. For some time, scientists suspected that a different enzyme, which usually breaks down the building blocks for crotonylation, might be failing in heart disease, leading to a buildup of the tags. However, the researchers found no evidence that this enzyme was reduced in their experiments. Instead, they showed that the problem is an active increase in the production of the tags, driven by the rise in FASN. This distinction is crucial because it changes the potential approach to treatment. Rather than trying to fix a broken breakdown enzyme, the focus might shift to controlling the fat-making enzyme that is driving the process.

By connecting the dots between lipid metabolism, cell signaling, and the epigenetic control of genes, this work offers a clearer picture of how the heart remodels itself. It reveals that the heart's response to stress is a coordinated effort involving multiple systems, where the machinery for making fat also helps decide which genes are turned on to build more muscle. While the researchers note that further studies are needed to confirm these findings in living animals and to explore how this pathway might be safely targeted in patients, the discovery provides a new, concrete target for understanding heart failure. It suggests that by understanding how the heart's metabolic state influences its genetic switches, we may one day be able to stop the heart from growing in the wrong way, keeping it healthy and functional for longer.

Drowning in papers in your field?

Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.

Try Digest →